treximet

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

POZEN Inc. Q3 2008 Earnings Call Transcript

Question-and-Answer Session Operator Operator instructions Your first question comes from the line of Angela Larson of SFG. Your line is open. Angela Larson – SFG Good morning and thanks for taking questions. John Plachetka Good morning Angela Larson – SFG Good morning. I was hoping...

Tags: Generic, Call Transcript, Earnings, Question, Pozen Inc., Treximet, Sales Strategy, Sales Force Management, Sales, Seeking Alpha

Earnings calls 2008-11-12

Additional Resources

POZEN, Inc. Q2 2008 Earnings Call Transcript

Question-and-Answer SessionOperator Operator Instructions Our first question comes from the line of Michael Tong with Wachovia Securities. Michael Tong - Wachovia Securities Hi, good morning. Bill, I just want to make sure I heard you correctly. Given your current revenue guidance and the breakout that you...

Tags: Pozen Inc.

Earnings calls 2008-08-25

POZEN Inc. Q1 2008 Earnings Call Transcript

Question-and-Answer Session Operator Operator instructions Your first question is from the line of Lucy Lu with Citi. Lucy Lu – Citigroup Thank you. Good morning. John Plachetka Good morning, Lucy. Lucy Lu – Citigroup Just curious, is your guidance on Treximet royalty revenue of $5...

Tags: Pozen Inc.

Earnings calls 2008-05-08

POZEN Announces Receipt of $20 Million in Milestone Payments from GlaxoSmithKline

CHAPEL HILL, N.C. -- POZEN Inc. (NASDAQ: POZN), today announced the receipt of a total of $20 million in milestone payments from GlaxoSmithKline GSK for the U.S. Food and Drug Administration approval of, and GSK's intent to commercialize, Treximet[TM] sumatriptan and naproxen sodium for the acute treatment of migraine in...

Tags: GlaxoSmithKline Plc., payment

Research articles 2008-04-28

Pozen.(Triangle)(Brief article)

CHAPEL HILL -- Pozen expects to hear by mid-April whether its migraine treatment will be approved by the federal Food and Drug Administration. In August, the agency requested ... CHAPEL HILL -- Pozen expects to hear by mid-April whether its migraine treatment will be approved by...

Tags: FDA

Research articles 2008-03-01

Marked Improvement Bodes Well for Pozen

Zacks.com submits: We are updating our financial model on Pozen POZN. Although GlaxoSmithKline GSK is not expected to report sales of Treximet until later in the month, we have seen data showing that prescription trends for the drug are showing a dramatic improvement over the past few weeks.For...

Tags: Biotech, Healthcare, Zacks.com, GlaxoSmithKline Plc., Pozen Inc.

External links 2009-04-15